Signature of B-CLL with different prognosis by shrunken centroids of surface antigen expression profiling

Journal of Cellular Physiology

Volumn 204, Issue 1, 2005, Pages 113-123

  Zucchetto, Antonella ^a   Sonego, Paolo ^a,d   Degan, Massimo ^a   Bomben, Riccardo ^a   Dal Bo, Michele ^a   Russo, Stefania ^a   Attadia, Vincenza ^a   Rupolo, Maurizio ^a   Buccisano, Francesco ^b   Del Principe, Maria Ilaria ^b   Del Poeta, Giovanni ^b   Pucillo, Carlo ^c   Colombatti, Alfonso ^a,c   Campanini, Renato ^d   Gattei, Valter ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA3 INTEGRIN; ALPHA4 INTEGRIN; BETA1 INTEGRIN; CD20 ANTIGEN; CD38 ANTIGEN; CD79B ANTIGEN; CYTIDINE DEAMINASE; IMMUNOGLOBULIN HEAVY CHAIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR ALPHA; MEMBRANE ANTIGEN; PADGEM PROTEIN; PROTEIN KINASE ZAP 70; SMLG ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL STRUCTURE; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; FEMALE; FLOW CYTOMETRY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; CLUSTER ANALYSIS; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPHENOTYPING; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN-TYROSINE KINASES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 20144365069     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20269     Document Type: Article

References (63)

1. Albesiano E, Messmer BT, Damle RN, Allen SL, Rai KR, Chiorazzi N. 2003. Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: Expression as multiple forms in a dynamic, variably sized fraction of the clone. Blood 102:3333-3339.
2. Armitage P, Berry G. 1987. Statistical methods in medical research. Oxford: Blackwell Scientific Publications. 559 p.
3. Baldini L, Cro L, Calori R, Nobili L, Silvestris I, Maiolo AT. 1992. Differential expression of very late activation antigen-3 (VLA-3)/VLA-4 in B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia. Blood 79:2688-2693.
4. Baumgarth N. 2000. A two-phase model of B-cell activation. Immunol Rev 176:171-180.
5. Chang B, Casali P. 1994. The CDR1 sequences of a major proportion of human germline Ig VH genes are inherently susceptible to amino acid replacement. Immunol Today 15:367-373.
6. Chiorazzi N, Ferrarini M. 2003. Chronic lymphocytic leukemia: Lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 21: 841-894.
7. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marce S, Lopez-Guillermo A, Campo E, Montserrat E. 2003. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775.
8. Damle RN, Wasil T, Fais F, Ghiotto F, Valette A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. 1999. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847.
9. Damle RN, Ghiotto F, Valette A, Albesiano E, Fais F, Yan XJ, Sison CP, Allen SL, Kolitz J, Schulman P, Vinciguerra VP, Budde P, Frey J, Rai KR, Ferrarini M, Chiorazzi N. 2002. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 99:4087-4093.
10. de la Fuente MT, Casanova B, Garcia-Gila M, Silva A, Garcia-Pardo A. 1999. Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: Correlation with Bcl-2 and Bax. Leukemia 13:266-274.
11. de la Fuente MT, Casanova B, Moyano JV, Garcia-Gila M, Sanz L, Garcia-Marco J, Silva A, Garcia-Pardo A. 2002. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 71:495-502.
12. de la Fuente MT, Casanova B, Cantero E, Hernandez del Cerro M, Garcia-Marco J, Silva A, Garcia-Pardo A. 2003. Involvement of p53 in alpha4beta1 integrin-mediated resistance of B-CLL cells to fludarabine. Biochem Biophys Res Commun 311:708-712.
13. De Zen L, Bicciato S, te Kronnie G, Basso G. 2003. Computational analysis of flow-cytometry antigen expression profiles in childhood acute lymphoblastic leukemia: An MLL/AF4 identification. Leukemia 17:1557-1565.
14. Degan M, Mazzocco FT, Di Francia R, Rossi FM, Pinto A, Gattei V. 2000. Normalizing complementary DNA by quantitative reverse transcriptase-polymerase chain reaction of beta2-microglobulin: Molecular monitoring of minimal residual disease in acute promyelocytic leukemia. Diagn Mol Pathol 9:98-109.
15. Degan M, Bomben R, Dal Bo M, Zucchetto A, Nanni P, Rupolo M, Steffan A, Attadia V, Ballerini PF, Damiani D, Pucillo C, Del Poeta G, Colombatti A, Gattei V. 2004a. Analysis of IgVH gene mutations in B-CLL according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical SHM machinery. Br J Haematol 126:29-42.
16. Degan M, Rupolo M, Dal Bo M, Stefanon A, Bomben R, Zucchetto A, Canton E, Berretta M, Nanni P, Steffan A, Ballerini PF, Damiani D, Pucillo C, Attadia V, Colombatti A, Gattei V. 2004b. Mutational status of IgVH genes consistent with antigen-driven selection but not percent of mutations has prognostic impact in B-cell chronic lymphocytic leukemia. Clin 5:123-126.
17. Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno AM, Capelli G, Tamburini A, Suppo G, Battaglia A, Del Principe MI, Del Moro B, Masi M, Amadori S. 2001. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 98:2633-2639.
18. Dorner T, Foster SJ, Brezinschek HP, Lipsky PE. 1998. Analysis of the hypermutational machinery and the impact of subsequent selection on the distribution of nucleotide changes in human VHDJH rearrangements. Immunol Rev 162:161-171.
19. Eisen MB, Spellman PT, Brown PO, Botstein D. 1998. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868.
20. Eksioglu-Demiralp E, Alpdogan O, Aktan M, Firatli T, Ozturk A, Budak T, Bayik M, Akoglu T. 1996. Variable expression of CD49d antigen in B cell chronic lymphocytic leukemia is related to disease stages. Leukemia 10:1331-1339.
21. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen SL, Schulman P, Vinciguerra VP, Rai K, Rassenti LZ, Kipps TJ, Dighiero G, Schroeder HW, Jr., Ferrarini M, Chiorazzi N. 1998. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 102:1515-1525.
22. Gattei V, Degan M, Gloghini A, De Iuliis A, Improta S, Rossi FM, Aldinucci D, Perin V, Serraino D, Babare R, Zagonel V, Gruss HJ, Carbone A, Pinto A. 1997. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 89:2048-2059.
23. Gattei V, Zucchetto A, Russo S, Stefanon A, Bomben R, Dal Bo M, Rupolo M, Canton E, Berretta M, Nanni P, Steffan A, Attadia V, Buccisano F, Del Poeta G, Colombatti A, Degan M. 2003. Immunophenotypic clustering of B-CLL identifies subsets with different prognosis without a strict correlation with IgVH mutational status and CD38 expression. Blood 102:667a (Abstract).
24. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M. 2001. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59. Blood 98:3383-3389.
25. Gu B, Dao LP, Wiley J. 2001. Impaired transendothelial migration of B-CLL lymphocytes: A defect linked to low L-selectin expression. Leuk Lymphoma 42:5-12.
26. Gurrieri C, McGuire P, Zan H, Yan XJ, Cerutti A, Albesiano E, Allen SL, Vinciguerra V, Rai KR, Ferrarini M, Casali P, Chiorazzi N. 2002. Chronic lymphocytic leukemia B cells undergo somatic hypermutation and intraclonal immunoglobulin VHDJH gene diversification. J Exp Med 196:629-639.
27. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. 1999. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854.
28. Hamblin T, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, Oscier DG. 2002. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99:1023-1029.
29. Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, Lepre J, Shah N, Kay NE. 2003. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res 1:346-361.
30. Klein U, Stolovitzky GA, Mattioli M, Cattoretti G, Husson HAF, Inghirami G, Cro L, Baldini L, Neri A, Califano A, Dalla-Favera R. 2001. Gene expression profiling of B chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194:1625-1638.
31. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P, Dohner H, Stilgenbauer S. 2002. VH mutational status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 1000:1410-1416.
32. Lane PJ, McConnell FM, Clark EA, Mellins E. 1991. Rapid signaling to B cells by antigen-specific T cells requires CD18/CD54 interaction. J Immunol 147:4103-4108.
33. Ley K. 2002. Integration of inflammatory signals by rolling neutrophils. Immunol Rev 186:8-18.
34. Likas A, Vlassisb N, Verbeekb JJ. 2003. The global k-means clustering algorithm. Pattern Recognit 36:451-461.
35. Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR. 2002. Relationship between p53 dysfunction, CD38 expression, and IgVH mutation in chronic lymphocytic leukemia. Blood 1000:1404-1409.
36. Lossos IS, Tibshirani R, Narasimhan B, Levy R. 2000. The inference of antigen selection on Ig genes. J Immunol 165:5122-5126.
37. Lublin DM, Atkinson JP. 1990. Decay-accelerating factor and membrane cofactor protein. Curr Top Microbiol Immunol 153:123-145.
38. Maloum K, Davi F, Merle-Beral H, Pritsch O, Magnac C, Vuillier F, Dighiero G, Troussard X, Mauro FF, Benichou J. 2000. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood 96:377-379.
39. Matutes E, Owusu-Ankomah K, Morilla R, arcia Marco J, Houlihan A, Que TH, Catovsky D. 1994. The immunological profile of B cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8:1640-1645.
40. Maynadié M, Picard F, Husson B, Chatelain B, Cornet Y, Le Roux G, Campos L, Dromelet A, Lepelley P, Jouault H, Imbert M, Rosenwadj M, Verge V, Bissieres P, Raphael M, Bene MC, Feuillard J, and (GEIL),G.d.I.d.L. 2002, Immunophenotypic clustering of myelodysplastic syndromes. Blood 2349-2356.
41. McCarthy H, Wierda WG, Barron LL, Cromwell CC, Wang J, Coombes KR, Rangel R, Elenitoba-Johnson KS, Keating MJ, Abruzzo LV. 2003. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood 101:4903-4908.
42. + T lymphocytes: Molecular dynamics and immunologic consequences. Semin Immunol 15:325-329.
43. Naylor M, Capra JD. 1999. Mutational status of Ig VH genes provides clinically valuable information in B-cell chronic lymphicytic leukemia. Blood 94:1837-1839.
44. Oppezzo P, Vuillier F, Vasconcelos Y, Dumas G, Magnac C, Payelle-Brogard B, Pritsch O, Dighiero G. 2003. Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation. Blood 101:4029-4032.
45. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, Hamblin TJ, Staudt LM, Oscier DG. 2004. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363:105-111.
46. Oscier DG, Thompsett A, Zhu D, Stevenson FK. 1997. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 89:4153-4160.
47. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, Corcoran MM, Chapman RM, Thomas PW, Copplestone JA, Orchard JA, Hamblin TJ. 2002. Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100:1177-1184.
48. Pittner BT, Morlan BW, Ballman KV, Kay NE, Jelinek DF. 2003. Leukemic B cells from CD38 positive but not CD38 negative B-CLL patients express heightened levels of alpha-4 integrin. Blood 102:670a.
49. Poudrier J, Owens T, 1994. CD54/intercellular adhesion molecule 1 and major histocompatibility complex II signaling induces B cells to express interleukin 2 receptors and complements help provided through CD40 ligation. J Exp Med 179:1417-1427.
50. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. 1975. Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234.
51. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. 2004. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N EnglJMed 351:893-901.
52. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM. 2001. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194:1639-1647.
53. Ruoslahti E. 1991. Integrins. J Clin Invest 87:1-5.
54. Shanafelt TD, Geyer SM, Kay NE. 2003. Prognosis at diagnosis: Integrating molecular biologic insights into clinical practice for patients with CLL. Blood 103:1202-1210.
55. Sherlock G. 2000. Analysis of large-scale gene expression data. Curr Opin Immunol 12:201-205.
56. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR. 2002. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68-74.
57. Spath H. 1980. Cluster analysis algorithms. Chichester, UK: Ellis Horwood Ltd. 197 p.
58. Spessotto P, Zucchetto A, Stefanon A, Gattei V, Wassermann B, Colombatti A. 2004. The ability to migrate on laminin-5 is associated with VH gene mutational status in chronic lymphocytic leukemia. Tumori 3:158 (Abstract).
59. Stevenson FK, Caligaris-Cappio F. 2004. Chronic lymphocytic leukemia: Revelations from the B-cell receptor. Blood 103:4389-4395.
60. Stratowa C, Loffler G, Lichter P, Stilgenbauer S, Haberl P, Schweifer N, Dohner H, Wilgenbus KK. 2001. CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int J Cancer 91:474-480.
61. Takada Y, Murphy E, Pil P, Chen C, Ginsberg MH, Hemler ME. 1991. Molecular cloning and expression of the cDNA for alpha 3 subunit of human alpha 3 beta 1 (VLA-3), an integrin receptor for fibronectin, laminin, and collagen. J Cell Biol 115:257-266.
62. Tibshirani R, Hastie T, Narasimhan B, Chu G. 2002. Diagnosis of multiple cancer types by Shrunken centroids of gene expression. Proc Natl Acad Sci USA 99:6567-6572.
63. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, Tibshirani R, Bolstein D, Altman RB. 2001. Missing value estimation methods for DNA microarrays. Bioinformatics 17:520-525.